1,721,466 research outputs found
[Complete diagnostic work-up provides the rational basis for the most appropriate therapy of myelodysplastic syndromes]
No full textMyelodysplastic syndromes are now classified according to the 2008 World Health Organization criteria. An accurate risk assessment requires a keen evaluation of disease-related factors to adapt treatment to patients age, expectations and comorbidities. A high proportion of MDS patients are not eligible for potentially curative and consequently intensive treatment because of advanced age and/or clinically relevant comorbidities and poor performance status. In these patients, a number of new agents are available or being developed but their use should be carefully guided by the chromosomal and genetic determinant of the disease
BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
No full textIn vitro acquired cellular senescence and aging-specific phenotype can be distinguished on the basis of specific mRNA expression
No full text
NEUTROPHILIC-CHRONIC MYELOID LEUKEMIA: A DISTINCT DISEASE WITH SPECIFIC MOLECULAR MARKER (BCR/ABL WITH C3/A2 JUNCTION))
No full text- …
